Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Underscores unmet need for a ...

The U.K. biopharmaceutical company said data from a Phase 2 study of eRapa, a treatment for familial adenomatous polyposis, showed the drug to be safe and well-tolerated among users. The treatment ...

Shares of Biodexa Pharmaceuticals skyrocketed nearly 50% on Monday, hitting their highest level since early December. The ...

Biodexa Pharmaceuticals PLC ("Biodexa” or "the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with ...

Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of ...

Biodexa Pharmaceuticals PLC has announced the appointment of Dr. Gary A. Shangold as Chief Medical Officer, effective immediately. CEO Stephen Stamp expressed enthusiasm for Dr. Shangold’s ...

Biodexa (NASDAQ:BDRX) stock soared 76% in morning trading after the company announced it has received FDA Fast Track designation for its drug eRapa for the treatment of familial adenomatous polyposis, ...

(RTTNews) - Biodexa Pharmaceuticals PLC (BDRX) announced the appointment of Gary Shangold as Chief Medical Officer with immediate effect. Most recently, Shangold was Chief Medical Officer of ...